
MarketOpen Podcast Episode 177: Identifai Genetics
In this episode, Eyal Miller, Group CEO of Identifai Genetics (ASX: ID1), discusses the company’s Windrose™ prenatal genetic screening technology, its US commercialisation strategy and the clinical development milestones ahead. Eyal takes listeners through how Windrose™ uses a maternal blood sample to assess fetal genetic information, how it differs from existing screening and the role of Windrose+ in the company’s technology development plans. The conversation also covers barriers to broader adoption, helping clinicians and expectant parents understand the technology’s capabilities and limitations, and the Inocras partnership supporting Identifai’s planned US market entry. Eyal also discusses priorities for the proposed $10 million IPO proceeds, the planned 600 patient US clinical validation study and the company’s goals for clinical adoption.
















